Incannex Healthcare Inc. IXHL
dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs.
2/3 clinical trial for the treatment of obstructive sleep apnea ("OSA") is an oral fixed-dose combination of dronabinol and
acetazolamide designed to act synergistically by targeting two different physiological pathways associated with the intermittent hypoxia
and hypercapnia that characterize OSA. In a proof-of-concept study conducted in Australia, as well as in the Phase 2 portion of our RePOSA
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $86.0K | $12.0K | — | — | $1.9M | $604.9K | — |
| R&D | $10.7M | $12.9M | $6.3M | — | — | — | — |
| SG&A | $13.1M | $17.2M | $8.0M | — | — | — | — |
| Total operating expenses | $23.9M | $30.1M | $49.7M | — | — | — | — |
| Operating income | -$23.8M | -$30.0M | -$49.7M | — | — | — | — |
| Interest expense | $303.0K | — | — | — | — | — | — |
| Pre-tax income | -$46.9M | -$18.4M | -$48.8M | — | — | — | — |
| Income tax | — | $30.0K | — | — | — | — | — |
| Net income | -$46.9M | -$18.5M | -$48.8M | -$14.9M | -$11.4M | -$4.7M | — |
| EPS, basic | -1.35 | -1.15 | -3.32 | — | — | — | — |
| EPS, diluted | -1.35 | -1.15 | -3.32 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 34.5M | 16.2M | 15.4M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.0M | $5.9M | $22.1M | $25.8M | — | — | — |
| Total current assets | $20.0M | $16.2M | $23.0M | — | — | — | — |
| Property, plant and equipment | $227.0K | $472.0K | $294.0K | — | — | — | — |
| Total assets | $20.4M | $17.0M | $23.8M | $37.9M | $9.3M | $4.2M | — |
| Accounts payable | — | $5.5M | $2.4M | — | — | — | — |
| Total current liabilities | $7.0M | $5.6M | $2.5M | — | — | — | — |
| Total liabilities | $7.1M | $5.8M | $3.0M | — | — | — | — |
| Retained earnings | -$157.6M | -$110.7M | -$92.2M | — | — | — | — |
| Total equity | $13.4M | $11.2M | $20.8M | $24.7M | $8.6M | $3.2M | -$417.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.5M | -$15.8M | -$10.7M | — | — | — | — |
| Depreciation and amortisation | $143.00B | $103.00B | $23.0M | — | — | — | — |
| Stock-based compensation | $2.6M | $8.9M | $2.1M | $1.5M | $600.0K | $565.4K | — |
| Capital expenditure | $8.0K | $277.0K | $316.0K | — | — | — | — |
| Investing cash flow | -$8.0K | -$277.0K | -$316.0K | — | — | — | — |
| Financing cash flow | $21.4M | — | $8.2M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-092837.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $604.9K | $1.9M | — | — | $12.0K | $86.0K |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$4.7M | -$11.4M | -$14.9M | -$48.8M | -$18.5M | -$46.9M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |